IADR 2021: Cortexyme Presents New Data on Potential New Periodontal Disease Treatment
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021.
Dentistry Today is The Nation’s Leading Clinical News Magazine for Dentists. Here you can get the latest dental news from the whole world quickly.
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021.
A new method for combating periodontitis could render the use of broad-spectrum antibiotics superfluous by only neutralizing the bacteria that causes the disease.